This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Bictegravir
From Proteopedia
(Difference between revisions)
| (4 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='98/989308/Cv/1'> | ||
Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir]. | Bictegravir (INN; BIC, formerly known as GS-9883) is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences. See also [https://en.wikipedia.org/wiki/Bictegravir Bictegravir]. | ||
| + | |||
| + | In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection<ref name="a5">[https://www.gilead.com/news-and-press/press-room/press-releases/2016/6/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV | Gilead".] Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.</ref> and the combination drug bictegravir/[[emtricitabine]]/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.<ref name="a6">[https://www.businesswire.com/news/home/20180207006071/en/U.S.-Food-Drug-Administration-Approves-Gilead%E2%80%99s-Biktarvy%C2%AE "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection"] (Press release). Gilead. 7 February 2018.</ref> | ||
<scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]). | <scene name='98/989308/Overall/2'>Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir</scene> ([[7ouh]]). | ||
| + | |||
| + | <scene name='98/989308/Overall/4'>Bictegravir inhibits integrase</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
| |||||||||||
References
- ↑ "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV | Gilead". Gilead. 20 June 2016. Archived from the original on 2 February 2017. Retrieved 20 January 2017.
- ↑ "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. 7 February 2018.
